Novartis and Medicines for Malaria Venture (MMV) have initiated a Phase IIb clinical trial of KAF156 to treat multidrug-resistant malaria in Africa.

KAF156 belongs to the imidazolopiperazines class of antimalarial compounds and is believed to have the potential to clear infection and also prevent the transmission of the malaria parasite.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase IIb trial is designed to evaluate the efficacy of KAF156 in combination with a new and improved formulation of an existing antimalarial drug called lumefantrine.

As part of the trial, various dosing combinations and dosing schedules of the combination will be tested in adults, adolescents and children.

"With the Phase IIb trial of KAF156-lumefantrine now underway, the MMV-Novartis partnership is drawing closer to the exciting prospect of such a new medicine that would be a powerful tool to fight the disease."

MMV CEO Dr David Reddy said: "To build on the gains made against malaria since the turn of the century, we need new medicines that are effective across all types of resistance patterns and geographies, and that are easy to administer, especially to children.

"With the Phase IIb trial of KAF156-lumefantrine now underway, the MMV-Novartis partnership is drawing closer to the exciting prospect of such a new medicine that would be a powerful tool to fight the disease."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial will initially be performed in adults in Mali, Africa and will be expanded to adolescents and children at 16 additional centres across a total of nine countries in Africa and Asia.

In a Phase IIa proof-of-concept trial, KAF156 was found to be fast-acting and potent in various stages of the parasite's lifecycle and demonstrated rapid clearance of Plasmodium falciparum, as well as Plasmodium vivax parasites.